Literature DB >> 22643561

Quality of life, muscle strength, and fatigue perception in patients on suppressive therapy with levothyroxine for differentiated thyroid carcinoma.

Dhiãnah Santini de Oliveira Chachamovitz1, Patrícia dos Santos Vigário, Mônica Fabíola Nogueira Cordeiro, Carmen Lucia Natividade de Castro, Mário Vaisman, Patrícia de Fátima dos Santos Teixeira.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the fatigue perception, the muscle function, and the health-related quality of life (QoL) in subclinical hyperthyroidism (SCH) induced by levothyroxine in the treatment of differentiated thyroid carcinoma, in comparison with a group of euthyroid (EU) subjects. PATIENTS AND METHODS: A cross-sectional study with 38 SCH individuals and 54 EU subjects was performed. They were submitted to Short Form-36 and Chalder questionnaires to evaluate QoL and fatigue, respectively. The tests performed to evaluate muscle function of upper and lower limbs were: maximum quadriceps isometric strength (QS); quadriceps fatigue resistance (T50% QS), QS at 30 seconds (QS30s); quadriceps functional capacity (QFC); maximum isometric handgrip strength (HS); fatigue handgrip resistance (T50% HS), HS at 30 seconds (HS30s); and functional capacity of the shoulder. RESULTS AND
CONCLUSIONS: The SCH patients had worse muscle function, regarding HS (25.19 ± 7.00 vs. 30.45 ± 9.98 kgf in EU, P = 0.009) and functional capacity of the shoulder (41.28 ± 48.36 vs. 56.68 ± 37.44 s in EU, P = 0.004). The self-perception of fatigue by Chalder questionnaire (23.91 ± 5.39 vs. 29.77 ± 7.03, P = 0.000) and the QoL in terms of functional capacity (70.20 ± 21.57 vs. 56.25 ± 28.79, P = 0.025), physical aspects (71.42 ± 36.44 vs. 45.83 ± 42.88, P = 0.004), pain (62.48 ± 22.20 vs. 50.05 ± 24.80, P = 0.035), and emotional aspects (70.74 ± 38.26 vs. 46.29 ± 44.56, P = 0.008) were also worse in SCH. In conclusion, the SCH was associated with alterations in the QoL, reduction in the muscle function of upper limbs, and higher degree of fatigue.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22643561     DOI: 10.1097/COC.0b013e318248d864

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

1.  Health Anxiety and Its Relationship to Thyroid-Hormone-Suppression Therapy in Patients with Differentiated Thyroid Cancer.

Authors:  Maximilian Zoltek; Therese M-L Andersson; Erland Axelsson; Christel Hedman; Catharina Ihre Lundgren
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

2.  Energy level and fatigue after surgery for thyroid cancer: A population-based study of patient-reported outcomes.

Authors:  David T Hughes; David Reyes-Gastelum; Kevin J Kovatch; Ann S Hamilton; Kevin C Ward; Megan R Haymart
Journal:  Surgery       Date:  2019-09-30       Impact factor: 3.982

3.  Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme.

Authors:  Eva-Maria Gamper; Lisa M Wintner; Margarida Rodrigues; Sabine Buxbaum; Bernhard Nilica; Susanne Singer; Johannes M Giesinger; Bernhard Holzner; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-13       Impact factor: 9.236

4.  The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma

Authors:  Nazli Gülsoy Kirnap; Özlem Turhan Iyidir; Yusuf Bozkuş; Şerife Mehlika Işildak; Cüneyd Anil; Sevde Nur Firat; Canan Demir; Asli Nar; Neslihan Başçil Tütüncü
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

5.  Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves' disease.

Authors:  Daiki Setoyama; Ho Yeop Lee; Ji Sun Moon; Jingwen Tian; Yea Eun Kang; Ju Hee Lee; Minho Shong; Dongchon Kang; Hyon-Seung Yi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-12-30       Impact factor: 12.910

6.  Systematic review of health-related quality of life following thyroid cancer.

Authors:  Emma G Walshaw; Mike Smith; Dae Kim; Jonathan Wadsley; Anastasios Kanatas; Simon N Rogers
Journal:  Tumori       Date:  2021-08-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.